Ming Qi

10.1k citations

106 papers · 3.8k indexed · 1 hit paper · h-index 25

Impact in

Hematology top 0.5%
- Multiple Myeloma Research and Treatments
Oncology top 2%
- Peptidase Inhibition and Analysis

Papers in

Hematology 69
- Multiple Myeloma Research and Treatments 68
Genetics 29
- Chronic Lymphocytic Leukemia Research 27

Co-authors: Xiang Qin Wojciech Zaręba Scott McNitt Jennifer L. Robinson Arthur J. Moss Ilan Goldenberg María‐Victoria Mateos Tahamtan Ahmadi
Journals: Blood (30 papers)Journal of Clinical Oncology (18 papers)British Journal of Haematology (4 papers)Clinical Cancer Research (3 papers)Annals of Hematology (3 papers)
Partner nations: United States Spain Belgium

In The Last Decade

Ming Qi

105 papers receiving 3.7k citations

Hit Papers

align trajectories log scale

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma 2016 · 1.1k citations

Peers

Countries citing papers authored by Ming Qi

Since Specialization

Citations

This map shows the geographic impact of Ming Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Qi more than expected).

Fields of papers citing papers by Ming Qi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Qi. The network helps show where Ming Qi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ming Qi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ming Qi Line = papers co-authored together Ming Qi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003) Annals of Hematology ·Hongmei Jing, Yang Li, Junyuan Qi, Lugui Qiu, Chengcheng Fu, Junmin Li, Min Yang, Ming Qi, Ni Fan, Jia Ji, Leandro Drazic, Yunan Li, Jie Jin	2022	3
2	Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study Annals of Hematology ·Shinsuke Iida, Takayuki Ishikawa, Chang Ki Min, Kihyun Kım, CA Boyd, Saad Z. Usmani, María‐Victoria Mateos, Hareth Nahi, Christoph Heuck, Xiang Qin, Dolly A. Parasrampuria, Katharine S. Gries, Ming Qi, Nizar J. Bahlis, Shigeki Ito	2021	5
3	CNV Radar: an improved method for somatic copy number alteration characterization in oncology BMC Bioinformatics ·David Soong, Jeran K. Stratford, Hervé Avet‐Loiseau, Nizar J. Bahlis, Faith E. Davies, Angela Dispenzieri, A. Kate Sasser, Jordan M. Schecter, Ming Qi, Chad Brown, Wendell Jones, Jonathan J. Keats, Daniel Auclair, Christopher Chiu, Jason Powers, Michael Schäffer	2020	11
4	Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses Advances in Therapy ·Xu Steven Xu, Philippe Moreau, Saad Z. Usmani, Sagar Lonial, Andrzej Jakubowiak, Albert Oriol, Amrita Krishnan, Joan Bladé, Man Luo, Yu‐Nien Sun, Honghui Zhou, Ivo Nnane, William Deraedt, Ming Qi, Jon Ukropec, Pamela L. Clemens	2020	9
5	Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies Clinical Lymphoma Myeloma & Leukemia ·Michèle Cavo, Meletios Α. Dimopoulos, Jesús F. San Miguel, María‐Victoria Mateos, Andrzej Jakubowiak, William Deraedt, Annette Lam, Tobias Kampfenkel, Ming Qi, Jianming He	2020	6
6	Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor Blood ·Katja Weisel, Pieter Sonneveld, María‐Victoria Mateos, Vânia Hungria, Andrew Spencer, Jane Estell, Wolney Barreto, Paolo Corradini, Chang‐Ki Min, Eva Medvedova, Maria Krevvata, Sonali Trivedi, Xiang Qin, Huiling Pei, Jon Ukropec, Rachel Kobos, Ming Qi, Ajay K. Nooka	2019	26
7	Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial Annals of Hematology ·Tomoaki Fujisaki, Takayuki Ishikawa, Hiroyuki Takamatsu, Kenshi Suzuki, Chang‐Ki Min, Jae Hoon Lee, Jianping Wang, Robin Carson, Wendy Crist, Ming Qi, Koji Nagafuji	2019	7
8	Effects of a specially designed aerobic dance routine on mild cognitive impairment Clinical Interventions in Aging ·Yi Zhu, Han Wu, Ming Qi, Sheng Wang, Qin Zhang, Li Zhou, Shiyan Wang, К.П. Радзівіл, Ting Wu, Ming Xiao, Siyu Yang, Hong Chen, Ling Zhang, Каретникова Наталья Петровна, Jinhui Ma, Tong Wang	2018	103
9	Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius Blood ·Saad Z. Usmani, Hareth Nahi, Brendan M. Weiss, Nizar J. Bahlis, Andrew Belch, Henk M. Lokhorst, Peter M. Voorhees, Paul G. Richardson, Clarissa Uhlar, Jianping Wang, Ming Qi, Sagar Lonial	2017	8
10	Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM) Blood ·Habte Yimer, Jason M. Melear, Edward A. Faber, William Bensinger, John M. Burke, Sriya Gunawardena, Séan Murphy, Heng Chen, Yana Lutska, Mohamed Darif, Anil Londhe, Ming Qi, Jon Ukropec, Thomas S. Lin, Robert M. Rifkin	2017	5
11	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma Blood ·Timothy Brighton, Simon J. Harrison, David Ghez, Brendan M. Weiss, Andreas Kirsch, Hila Magen, Mercedes Gironella, Albert Oriol, Matthew Streetly, Xiang Qin, Rajesh Bandekar, Peter Hu, Ming Qi, Shu Yuanzhao, Hartmut Goldschmidt	2017	5
12	Interim Safety Analysis of a Phase 2 Randomized Study of Daratumumab (Dara), Lenalidomide (R), Bortezomib (V), and Dexamethasone (d; Dara-Rvd) Vs. Rvd in Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) Blood ·Peter M. Voorhees, Luciano J. Costa, Brandi Reeves, Nitya Nathwani, Cesar Rodriguez, Yana Lutska, Elena Ginobbi, Huiling Pei, Jon Ukropec, Ming Qi, Thomas S. Lin, Paul G. Richardson	2017	3
13	The Multicentric Castleman's Disease (Mcd) -Symptom Scale (Mcd-Ss): Development and Validation of A Patient-Reported Outcome (Pro) Measure for An Ultra-Orphan Disease Value in Health ·Corey Casper, SJ Rozzo, Margaret Rothman, San Antonio Chapter, Kai Fai Ho, Ming Qi, Jessica Vermeulen, Jim Cavet	2014	6
14	A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease Clinical Cancer Research ·Razelle Kurzrock, Peter M. Voorhees, Corey Casper, Richard R. Furman, Luis Fayad, Sagar Lonial, Hossein Borghaei, Sundar Jagannath, Lubomir Sokol, Saad Z. Usmani, Helgi van de Velde, Xiang Qin, Thomas A. Puchalski, Brett M. Hall, Manjula Reddy, Ming Qi, Frits van Rhee	2013	166
15	Prognostic implications of mutation-specific QTc standard deviation in congenital long QT syndrome Heart Rhythm ·Paul T. Hohe, Arthur J. Moss, Coeli M. Lopes, Alon Barsheshet, Scott McNitt, Wojciech Zaręba, Jennifer L. Robinson, Emanuela H. Locati, Michael J. Ackerman, Jesaia Benhorin, Elizabeth S. Kaufman, Pyotr G. Platonov, Ming Qi, Wataru Shimizu, Jeffrey A. Towbin, G. Michael Vincent, Arthur A.M. Wilde, Li Zhang, Ilan Goldenberg	2013	13
16	A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer Investigational New Drugs ·Gary R. Hudes, Scott T. Tagawa, Young E. Whang, Ming Qi, Xiang Qin, Thomas A. Puchalski, Manjula Reddy, Mark Cornfeld, Mario A. Eisenberger	2012	54
17	Correlation between cognitive function and the association fibers in patients with Alzheimer’s disease using diffusion tensor imaging Journal of Clinical Neuroscience ·侯建国, Arnaldo Antonio Martino, Hong Cheng, Yunjie Chen, 修一島田, Ming Qi, Zhenyu Jia, S Lakshmi Priya, Xunning Hong	2012	20
18	Risk of Fatal Arrhythmic Events in Long QT Syndrome Patients After Syncope Journal of the American College of Cardiology ·Christian Jøns, Arthur J. Moss, Ilan Goldenberg, Judy Liu, Scott McNitt, Wojciech Zaręba, Ming Qi, Jennifer L. Robinson	2010	84
19	Long QT Syndrome and Pregnancy Journal of the American College of Cardiology ·Rahul Seth, Arthur J. Moss, Scott McNitt, Wojciech Zaręba, Mark Andrews, Ming Qi, Jennifer L. Robinson, Ilan Goldenberg, Michael J. Ackerman, Jesaia Benhorin, Elizabeth S. Kaufman, Emanuela H. Locati, Carlo Napolitano, Silvia G. Priori, Peter J. Schwartz, Jeffrey A. Towbin, G. Michael Vincent, Li Zhang	2007	214
20	Safety and Efficacy of Flecainide in Subjects with Long QT‐3 Syndrome (ΔKPQ Mutation): A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial Annals of Noninvasive Electrocardiology ·Arthur J. Moss, John R. Windle, William J. Hall, Wojciech Zaręba, Jennifer L. Robinson, Scott McNitt, D. Brayshaw, Spencer Rosero, James P. Daubert, Ming Qi, Ashley Rasmussen, A S Manalan	2005	90

About Ming Qi

Ming Qi is a scholar working on Hematology, Genetics, Oncology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging, having authored 106 papers that have together received 3.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (68 papers), Chronic Lymphocytic Leukemia Research (27 papers), Peptidase Inhibition and Analysis (20 papers), Lymphoma Diagnosis and Treatment (17 papers), Monoclonal and Polyclonal Antibodies Research (16 papers), Protein Degradation and Inhibitors (15 papers), Viral-associated cancers and disorders (14 papers) and Cardiac electrophysiology and arrhythmias (14 papers). The work is most often cited by research in Hematology (1.8k citations), Oncology (1.5k citations), Cardiology and Cardiovascular Medicine (1.1k citations), Genetics (369 citations) and Molecular Biology (1.8k citations). Ming Qi has collaborated with scholars based in United States, Spain and Belgium. Frequent co-authors include Xiang Qin, Wojciech Zaręba, Scott McNitt, Jennifer L. Robinson, Arthur J. Moss, Ilan Goldenberg, María‐Victoria Mateos, Tahamtan Ahmadi, Katja Weisel and Ajay K. Nooka. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Clinical Cancer Research and Annals of Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact